CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure

Atherosclerosis

Volumn 190, Issue 1, 2007, Pages 156-166

  Campean, Valentina ^a   Neureiter, Daniel ^a   Nonnast Daniel, Barbara ^a   Garlichs, Christoph ^a   Gross, Marie Luise ^b   Amann, Kerstin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Department of Pathology ^*  (Germany)

Author keywords

Atherosclerosis; CD154; CD40; Chronic kidney disease; Inflammation

Indexed keywords

C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND;

ADULT; AGED; ANTIGEN EXPRESSION; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL INFILTRATION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MALE; MUSCLE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; UREMIA;

AGED; AGED, 80 AND OVER; ANTIGENS, CD40; B-LYMPHOCYTES; C-REACTIVE PROTEIN; CALCINOSIS; CD40 LIGAND; CORONARY ARTERIOSCLEROSIS; ENDOTHELIAL CELLS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MACROPHAGES; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VASCULITIS;

EID: 33845379988     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.01.014     Document Type: Article

References (51)

1. Braun J., Oldendorf M., Moshage W., et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27 (1996) 394-401
2. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
3. Lindner A., Charra B., Sherrard D.J., and Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290 (1974) 697-701
4. Oh J., Wunsch R., Turzer M., et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106 (2002) 100-105
5. Goodman W.G., London G., Amann K., et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 43 (2004) 572-579
6. Raggi P., Boulay A., Chasan-Taber S., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J Am Coll Cardiol 39 (2002) 695-701
7. Schwarz U., Buzello M., Ritz E., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transpl 15 (2000) 218-223
8. Moe S.M., O'Neill K.D., Duan D., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61 (2002) 638-647
9. Rostand S.G., Gretes J.C., Kirk K.A., Rutsky E.A., and Andreoli T.E. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 16 (1979) 600-611
10. Ritz E., and McClellan W.M. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol 15 (2004) 513-516
11. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108 (2003) 2154-2169
12. Zimmermann J., Herrlinger S., Pruy A., Metzger T., and Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 (1999) 648-658
13. Buzello M., Tornig J., Faulhaber J., et al. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14 (2003) 311-316
14. Oberg B.P., McMenamin E., Lucas F.L., et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65 (2004) 1009-1016
15. Shlipak M.G., Fried L.F., Crump C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003) 87-92
16. Landray M.J., Wheeler D.C., Lip G.Y., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 43 (2004) 244-253
17. Collins T., and Cybulsky M.I. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 107 (2001) 255-264
18. Krzesz R., Wagner A.H., Cattaruzza M., and Hecker M. Cytokine-inducible CD40 gene expression in vascular smooth muscle cells is mediated by nuclear factor kappaB and signal transducer and activation of transcription-1. FEBS Lett 453 (1999) 191-196
19. Bavendiek U., Libby P., Kilbride M., et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappaB, and Egr-1. J Biol Chem 277 (2002) 25032-25039
20. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
21. Hansson G.K., Libby P., Schonbeck U., and Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91 (2002) 281-291
22. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
23. Schwedler S., Amann K., Wernicke K., et al. Native C-reactive protein (CRP) increases, whereas modified CRP reduces atherosclerosis in ApoE-knockout-mice. Circulation 112 (2005) 1016-1023
24. Buchner K., Henn V., Grafe M., et al. CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis. J Pathol 201 (2003) 288-295
25. Schonbeck U., Mach F., and Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol 32 (2000) 687-693
26. Schonbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
27. de Boer O.J., Becker A.E., and van der Wal A.C. T lymphocytes in atherogenesis-functional aspects and antigenic repertoire. Cardiovasc Res 60 (2003) 78-86
28. Hakkinen T., Karkola K., and Yla-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 437 (2000) 396-405
29. Bruemmer D., Riggers U., Holzmeister J., et al. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions. Am J Cardiol 87 (2001) 21-27
30. Lutgens E., Gorelik L., Daemen M.J., et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 5 (1999) 1313-1316
31. Lutgens E., Cleutjens K.B., Heeneman S., et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 97 (2000) 7464-7469
32. Schonbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
33. Stary H.C. The development of calcium deposits in atherosclerotic lesions and their persistence after lipid regression. Am J Cardiol 88 (2001) 16E-19E
34. Stintzing S., Heuschmann P., Barbera L., et al. Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. Ann Vasc Surg (2005)
35. Neureiter D., Heuschmann P., Stintzing S., et al. Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate. Atherosclerosis 168 (2003) 153-162
36. Mach F., Schonbeck U., Sukhova G.K., Atkinson E., and Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998) 200-203
37. Mach F., Schonbeck U., Sukhova G.K., et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 94 (1997) 1931-1936
38. Karmann K., Hughes C.C., Schechner J., Fanslow W.C., and Pober J.S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 92 (1995) 4342-4346
39. de Boer O.J., van der Wal A.C., Teeling P., and Becker A.E. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization?. Cardiovasc Res 41 (1999) 443-449
40. Falk E. Why do plaques rupture?. Circulation 86 (1992) III30-III42
41. van der Wal A.C., Becker A.E., van der Loos C.M., Tigges A.J., and Das P.K. Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to inflammation: a concept. Coron Artery Dis 5 (1994) 463-469
42. Szabolcs M.J., Cannon P.J., Thienel U., et al. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease. Virchows Arch 437 (2000) 149-159
43. Dong Q., and Wright J.R. Expression of C-reactive protein by alveolar macrophages. J Immunol 156 (1996) 4815-4820
44. Hetland G., Johnson E., Royset P., and Eskeland T. Human alveolar macrophages and monocytes generate the functional classical pathway of complement in vitro. Acta Pathol Microbiol Immunol Scand [C] 95 (1987) 117-122
45. Blacher J., Lndon G.M., Safar M.E., and Mourad J.J. Influence of age and end-stage renal disease on the stiffness of carotid wall material in hypertension. J Hypertens 17 (1999) 237-244
46. Block G.A., Hulbert-Shearon T.E., Levin N.W., and Port F.K. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31 (1998) 607-617
47. Chertow G.M., Raggi P., Chasan-Taber S., et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transpl 19 (2004) 1489-1496
48. Ridker P.M., and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 109 (2004) 1955-1959
49. Varo N., de Lemos J.A., Libby P., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
50. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
51. Malyszko J., Malyszko J.S., Hryszko T., and Mysliwiec M. Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coagul Fibrin 15 (2004) 463-467